Prostate Adenocarcinoma: Correlation between miRseq expression and clinical features
Maintained by Juok Cho (Broad Institute)
Overview
Introduction

This pipeline uses various statistical tests to identify miRs whose expression levels correlated to selected clinical features.

Summary

Testing the association between 484 genes and 3 clinical features across 125 samples, statistically thresholded by Q value < 0.05, 1 clinical feature related to at least one genes.

- 3 genes correlated to 'NEOADJUVANT.THERAPY'.

- HSA-MIR-200B , HSA-MIR-200C , HSA-MIR-3605

- No genes correlated to 'AGE', and 'RADIATIONS.RADIATION.REGIMENINDICATION'.

Results
Overview of the results

Complete statistical result table is provided in Supplement Table 1

Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of genes that are significantly associated with each clinical feature at Q value < 0.05.

Clinical feature | Statistical test | Significant genes | Associated with |  | Associated with |
--- | --- | --- | --- | --- | --- | ---
AGE | Spearman correlation test | N=0 |  |  |  |
RADIATIONS RADIATION REGIMENINDICATION | t test | N=0 |  |  |  |
NEOADJUVANT THERAPY | t test | N=3 | yes | N=1 | no | N=2

Clinical variable #1: 'AGE'

No gene related to 'AGE'.

Table S1. Basic characteristics of clinical feature: 'AGE'

AGE | Mean (SD) | 61.02 (6.6)
| Significant markers | N = 0

Clinical variable #2: 'RADIATIONS.RADIATION.REGIMENINDICATION'

No gene related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.

Table S2. Basic characteristics of clinical feature: 'RADIATIONS.RADIATION.REGIMENINDICATION'

RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N
| NO | 5
| YES | 120
| Significant markers | N = 0

Clinical variable #3: 'NEOADJUVANT.THERAPY'

3 genes related to 'NEOADJUVANT.THERAPY'.

Table S3. Basic characteristics of clinical feature: 'NEOADJUVANT.THERAPY'

NEOADJUVANT.THERAPY | Labels | N
| NO | 3
| YES | 122
| Significant markers | N = 3
| Higher in YES | 1
| Higher in NO | 2

List of 3 genes differentially expressed by 'NEOADJUVANT.THERAPY'

Table S4. Get Full Table List of 3 genes differentially expressed by 'NEOADJUVANT.THERAPY'

| T(pos if higher in 'YES') | ttestP | Q | AUC
--- | --- | --- | --- | ---
HSA-MIR-200B | -7.24 | 1.144e-08 | 3.85e-06 | 0.8115
HSA-MIR-200C | -10.93 | 4.108e-08 | 1.38e-05 | 0.9071
HSA-MIR-3605 | 10.66 | 6.553e-05 | 0.0219 | 0.9256

Figure S1. Get High-res Image As an example, this figure shows the association of HSA-MIR-200B to 'NEOADJUVANT.THERAPY'. P value = 1.14e-08 with T-test analysis.

Methods & Data
Input

- Expresson data file = PRAD.miRseq_RPKM_log2.txt

- Clinical data file = PRAD.clin.merged.picked.txt

- Number of patients = 125

- Number of genes = 484

- Number of clinical features = 3

Correlation analysis

For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R

Student's t-test analysis

For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] Spearman, C, The proof and measurement of association between two things, Amer. J. Psychol 15:72-101 (1904)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)
Copyright © 2012 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle